You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

19 Results
Guidelines and Advice
Status: Current
ID: PET 17
Jan 2017
Guidelines and Advice
Status: Current
ID: PET 18
May 2017
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Oct 2017
Guidelines and Advice
Nov 2017
Guidelines and Advice
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jan 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
Jan 2025
Drug
Other Name(s): Vectibix®
Jan 2025

Pages